Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sue Robinson

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Leukemia & Lymphoma|January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group StudyMichael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Cancer|November 6, 2009
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter StudyBrad S Kahl, Nancy L Bartlett, John P Leonard, et al.
Leukemia & Lymphoma|March 11, 2020
IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemiaSarit Assouline, Lilian Amrein, Raquel Aloyz, et al.
Leukemia & Lymphoma|January 18, 2024
Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practiceVersha Banerji, Andrew Aw, Nicole Laferriere, et al.
British Journal of Haematology|February 19, 2021
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN studyStephan Stilgenbauer, Francesc Bosch, Osman Ilhan, et al.
Blood Advances|May 13, 2020
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORALSarit Assouline, Shen Li, Christian Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent studyJonathan W Friedberg, Philip Cohen, Ling Chen, et al.
International Journal of Laboratory Hematology|January 5, 2023
Defining ferritin clinical decision limits to improve diagnosis and treatment of iron deficiency: A modified Delphi studyKanza Naveed, Nicola Goldberg, Eliane Shore, et al.
Plos One|April 18, 2015
A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in NepalAjit Rayamajhi, Sam Nightingale, Nisha Keshary Bhatta, et al.
Plos One|August 14, 2015
Correction: A Preliminary Randomized Double Blind Placebo-Controlled Trial of Intravenous Immunoglobulin for Japanese Encephalitis in NepalAjit Rayamajhi, Sam Nightingale, Nisha Keshary Bhatta, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group StudyMichael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Cancer|November 6, 2009
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter StudyBrad S Kahl, Nancy L Bartlett, John P Leonard, et al.
Leukemia & Lymphoma|March 11, 2020
IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemiaSarit Assouline, Lilian Amrein, Raquel Aloyz, et al.
Leukemia & Lymphoma|January 18, 2024
Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practiceVersha Banerji, Andrew Aw, Nicole Laferriere, et al.
British Journal of Haematology|February 19, 2021
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN studyStephan Stilgenbauer, Francesc Bosch, Osman Ilhan, et al.
Blood Advances|May 13, 2020
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORALSarit Assouline, Shen Li, Christian Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent studyJonathan W Friedberg, Philip Cohen, Ling Chen, et al.
International Journal of Laboratory Hematology|January 5, 2023
Defining ferritin clinical decision limits to improve diagnosis and treatment of iron deficiency: A modified Delphi studyKanza Naveed, Nicola Goldberg, Eliane Shore, et al.
Plos One|April 18, 2015
A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in NepalAjit Rayamajhi, Sam Nightingale, Nisha Keshary Bhatta, et al.
Plos One|August 14, 2015
Correction: A Preliminary Randomized Double Blind Placebo-Controlled Trial of Intravenous Immunoglobulin for Japanese Encephalitis in NepalAjit Rayamajhi, Sam Nightingale, Nisha Keshary Bhatta, et al.
Pageof 5